


The Impact of Responsible AI on Healthcare: Challenges and Opportunities Ahead
Key takeaways: AI’s ability to quickly analyze and integrate vast, diverse data, identify patterns, and make accurate predictions presents significant opportunities in clinical research and drug development. Advanced analytics, predictive modeling, and machine...
Monitoring Potential Adverse Drug Events: Why Real-World Data is Key to Drug Safety
Adverse Drug Events (ADEs) or Adverse Drug Reactions (ADRs) continue to be a concern both in new and existing medicines. According to Medication Safety Data published by the U.S. Centers for Disease Control and Prevention (CDC), ADEs cause more than 1.5 million...
Real-World Data: Opening New Doors in Oncology Research and Patient Care
In the dynamic world of healthcare, real-world data (RWD) and the real-world evidence (RWE) derived from it stand as a crucial pillar for informed insights and actions. No where is this more evident than in oncology, where RWD and RWE are delivering on four key...
SCOPE 2025: Putting Patients at the Heart of Research
Clinical trials are the bedrock of medical advancement, but they often grapple with a persistent challenge: ensuring diverse and representative participation. This issue isn’t just a matter of ethics—it’s crucial for delivering effective, equitable healthcare...
TriNetX’s Founding CEO Announces Plans to Step Down
After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX’s Board CAMBRIDGE, MA – January 9, 2025 – TriNetX, the largest global source of real-world data, today announced that Gadi Lachman, the Company’s Founder, President and CEO, will step...
Revolutionizing Research and Clinical Trials: Innovating Today for a Healthier Tomorrow
In an era defined by rapid advancements in technology and science, healthcare research and clinical trials are undergoing a transformative shift. At the heart of this revolution is data—vast, diverse, and ever-growing—and the collaborative efforts of stakeholders...
Driving Change in Cancer Care: How Real-World Evidence is Revolutionizing Health Technology Assessments and Regulatory Standards
The use of real-world evidence (RWE) in regulatory decision-making and health technology assessments (HTA) is gaining traction, particularly in the evolving landscape of oncology pharmacotherapeutics in Europe where navigating the drug approval and market access...
With new diversity guidance, EHR data plus AI will be critical
In June 2024, the U.S. Food and Drug Administration (FDA) issued draft guidance outlining the need for “Diversity Action Plans” as a way for clinical trial sponsors to demonstrate their consideration toward trial representation. Affecting phase 3 studies, and others...